Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment
M. Kimura, Shiori Yamada, M. Go, S. Yasuda, H. Toyoda, E. Usami
{"title":"Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment","authors":"M. Kimura, Shiori Yamada, M. Go, S. Yasuda, H. Toyoda, E. Usami","doi":"10.3892/ol.2024.14464","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":508560,"journal":{"name":"Oncology Letters","volume":"43 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/ol.2024.14464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
